ScholarWorks@Korea University College of Medicine: Yim, Hyung Joon

Detailed Information

Yim, Hyung Joon (임형준)

Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Hepatocellular carcinoma:25||hepatocellular carcinoma:15||liver cirrhosis:15||Liver cirrhosis:13||chronic hepatitis B:13||Prognosis:12||Chronic hepatitis B:11||Hepatitis B virus:10||prognosis:8||entecavir:8||Helicobacter pylori:7||Sorafenib:7||Lamivudine:7||Hepatitis B:7||hepatitis B virus:6||Adefovir:6||Resistance:6||Entecavir:6||Cirrhosis:6||Mortality:5||cirrhosis:5||Survival:4||survival:4||cystatin C:4||transient elastography:4||treatment:4||hepatitis B:4||lamivudine:4||liver fibrosis:4||Hepatic arterial infusion chemotherapy:4||Acute hepatitis A:4||Recurrence:4||Transarterial chemoembolization:3||Tenofovir:3||Sarcopenia:3||concomitant therapy:3||Treatment:3||resistance:3||Risk factor:3||Relapse:3||acute decompensation:3||Chronic:3||eradication:3||Colonoscopy:3||Cholestasis:3||recurrence:3||liver stiffness:3||mortality:3||Hepatitis C:3||Chronic hepatitis C:3||Alcoholic hepatitis:3||Corticosteroid:3||Korea:3||antiviral therapy:3||tenofovir:3||Liver stiffness:3||acuteonchronic liver failure:3||drug therapy:3||Therapy:3||hepatorenal syndrome:3||antivirals:2||Portal hypertension:2||ascites:2||Hepatic stellate cells:2||5Fluorouracil:2||Interferon:2||Portal vein tumor thrombosis:2||Hepatitis A:2||nonalcoholic fatty liver disease:2||Fibrosis:2||Cisplatin:2||Prevention:2||Sustained virological response:2||chronic:2||performance:2||clevudine:2||combination:2||combination drug therapy:2||Propofol:2||constipation:2||Chemotherapy:2||prediction model:2||Besifovir:2||creatinine:2||proton pump inhibitor:2||Alanine aminotransferase:2||decompensation:2||renal dysfunction:2||risk prediction:2||Hepatitis C virus:2||Endoscopy:2||Nephrotoxicity:2||Radiotherapy:2||Choledocholithiasis:2||Guidelines:2||sorafenib:2||Variceal bleeding:2||Nonalcoholic fatty liver disease:2||genotype:2||Nonalcoholic steatohepatitis:2||survival rate:2||Response:2||Liver:2||Ribavirin:2||hepatitis:2||Hepatocellular Carcinoma:2||hepatitis B e antigen:2||hepatocellular:2||acute kidney injury:2||Balloonoccluded retrograde transvenous obliteration:2||adefovir:2||administration and dosage:2||MELD:2||HBsAg:2||Drug Resistance:2||MRI:2||Complication:2||ammonia:2||Durability:2||Carcinoma:2||liver transplantation:2||Peritonitis:2||Antiviral resistance:2||FibroScan:2||HBeAgnegative chronic hepatitis B:1||HBsAg loss:1||HCC:1||Handfoot skin reaction:1||Hemangioma:1||Hepacivirus:1||Hepatic artery:1||Hepatic decompensation:1||Hepatic encephalopathy:1||Hepatic resection:1||Hepatic venous pressure gradient:1||Hepatitis B Surface Antigens:1||Hepatitis B core antigens:1||Hepatitis B surface antigen:1||Hepatitis B surface antigens:1||Hepatitis B virus (HBV):1||Hepatitis B, Chronic:1||Hepatitis B, chronic:1||Hepatitis C virus (HCV):1||Hepatitis C virus clinical trials:1||Hepatitis C virus treatment:1||Hepatitis C, clinical:1||Hepatitis/Viral/Chronic hepatitis B:1||Hepatocellular:1||Hepatocellular carcinoma (HCC):1||Hepatorenal syndrome:1||Hereditary nonpolyposis colon cancer:1||High dose:1||Histologic activity index:1||Histology:1||Hong Kong Liver Cancer:1||HydroxymethylglutarylCoA reductase inhibitors:1||IgM antiHAV:1||Immunohistochemical stain:1||Inactive carrier:1||Incidence:1||Infected pancreatic necrosis:1||Inferior vena cava:1||Inflammasome:1||Inflammatory bowel disease:1||Interferon alfa:1||Interferongamma:1||Intervention:1||Intestinal surgery:1||Intraductal papillary neoplasm of the bile duct:1||Iron Therapy:1||Jejunal neoplasm:1||KASL guidelines:1||Kidney tubules, proximal:1||Klatskin's tumor:1||Klatskin암:1||Korean:1||Lamivudine Resistance:1||Laparoscopic surgery:1||Ledipasvir:1||Lemmel's Syndrome:1||Lens culinaris agglutininreactive fraction of alphafetoprotein:1||Lenvatinib mesylate:1||Life style:1||Liver diseases:1||Liver fibrosis:1||Liver neoplasm:1||Liver resection:1||Low dose:1||MELDNa:1||MRE:1||MUC3:1||MUC5AC:1||MUC6:1||Macrovascular Invasion:1||Maddrey's discriminant function:1||Magnetic resonance imaging:1||Malignant biliary obstruction:1||Mapping manometry:1||Mapping 내압검사:1||Metabolic syndrome:1||Metastasis:1||Microorganism:1||Midazolam:1||Midesophageal diverticulum:1||Milan criteria:1||Milk fat globuleEGF factor8:1||Molecular targeted therapy:1||Morbidity:1||Mortality rate:1||Multidetector computerized tomography (MDCT):1||Mutation:1||NacetylbetaDglucosaminidase:1||NacetylbetadGlucosaminidase:1||NacetylβD glucosaminidase:1||Natural killer cell:1||Necroinflammation:1||Necrosis:1||Neoplasm staging:1||Neutrophil:1||Noninferiority trial:1||Noninvasive diagnosis:1||Nonalcoholic fatty liver:1||Nucleoside analogue:1||Nucleoside/nucleotide analog:1||Nucleotide analogue:1||Nucleotidebinding and oligomerization domainlike receptor:1||Offtreatment:1||Osteomalacia:1||Osteopontin:1||Pain:1||Pancreatic abscess:1||Pancreatic involvement:1||Pancreatic pseudocyst:1||Pancreatitis:1||Partial virological response:1||Pathogenesis:1||Pegylated interferon alfa2a:1||Pegylated interferon alfa2b:1||Pegylated interferon alpha:1||Pentoxifylline:1||Periampullary Diverticulitis:1||Peritoneal implantation:1||Peroxisome proliferatoractivated receptors delta:1||PexaVec:1||Platelet:1||Portal vein:1||Portal vein invasion:1||Portal vein thrombosis:1||Positron emission tomography (PET):1||Prediction:1||Prediction model:1||Predictors:1||Pregnancy:1||Primary biliary cirrhosis:1||Prognostic factors:1||Prophylaxis:1||Protein induced by vitamin K absence or antagonistII:1||Protein kinase inhibitor:1||Prothrombin induced by vitamin K deficiency or antagonist II:1||Pseudomelanosis:1||Pseudomembranous:1||Psoas muscle:1||Pulmonary arteriovenous malformation:1||Pulmonary hypertension:1||RNA:1||Radiofrequency ablation:1||Reactivation:1||Realworld study:1||Rebleeding:1||Reflex:1||Rescue Therapy:1||Response evaluation criteria in solid tumors:1||Reversal:1||Rhabdomyolysis:1||Rifampin:1||Right atrium:1||Risk Factor:1||Risk assessment:1||Risk factors:1||SARSCoV2:1||Safety:1||Salvage Liver transplantation:1||Score:1||Scoring system:1||Sedation:1||Sedative endoscopy:1||Segmental esophageal dysmotility:1||Segmental hypotonic peristalsis:1||Segmentectomy:1||Sequential organ failure assessment:1||Serum MicroRNA:1||Severe acute pancreatitis:1||Sex:1||Signaling pathway:1||Skin ulcer:1||Small Bowel:1||Small cell carcinoma:1||Small cell neuroendocrine carcinoma:1||Socioeconomic status:1||Sodium:1||Sofosbuvir:1||Splenomegaly:1||Stage:1||Stomach:1||Stroke:1||Suboptimal:1||Surgery:1||Synchronous double cancer:1||Systemic amyloidosis:1||TACE:1||Telbivudine:1||Terlipressin:1||Therapeutics:1||Thrombosis:1||Thyroid autoantibody:1||Thyroid dysfunction:1||Tomography:1||Toxic hepatitis:1||Transient elastography:1||Transmission:1||Treatment failure:1||Trim22:1||Turner's syndrome:1||Ulcerative colitis:1||Ultrasonography:1||Urea cream:1||Variceal hemorrhage:1||Variceal obliteration:1||Vascular plugassisted retrograde transvenous obliteration:1||Vasopressor:1||Viral hepatitis:1||Viremia:1||Vitamin D:1||Xray computed:1||Yersinia:1||Yersinia infections:1||Yersinia pseudotuberculosis:1||Young:1||Zebrafish:1||acute hepatitis A:1||acute tubular necrosis:1||acylCoA oxidase:1||adverse outcomes:1||aetiology:1||alanine aminotransferase:1||alcoholic:1||alcoholic hepatitis:1||alpha fetoprotein:1||alt normalization:1||aminotransferase:1||amoxicillin:1||antibiotics:1||antisense oligonucleotide:1||antithrombotics:1||antiviral agent:1||antiviral agents:1||antiviral resistance:1||antiviral treatment:1||apolipoprotein:1||bacteremia:1||beta oxidation:1||biochemical response:1||biomarker:1||bismuth salts:1||bleeding ulcer:1||body mass index:1||bone density:1||breast cancer:1||cancer:1||carcinogenesis:1||carcinoma:1||cardiovascular events:1||catheter ablation:1||chronic colitis:1||chronic liver disease:1||chronic liver failure:1||comparison:1||complications:1||core promoter variants:1||corticosteroid:1||cyclooxygenase2 inhibitor:1||cytotoxic chemotherapy:1||decompensated cirrhosis:1||discontinuation:1||durability:1||eGFR:1||elastography:1||elicobacter pylori:1||empirical treatment:1||encephalopathy:1||endoscopic resection:1||esophageal and gastric varices:1||expiration:1||fatty acid:1||fibrosis:1||gastric cancer:1||gastrografin:1||genetic analysis:1||genetic variations:1||glutaminase:1||gross morphology:1||haptoglobin:1||hcc:1||hepatic decompensation:1||hepatic encephalopathy:1||hepatic hydrothorax:1||hepatitis A virus:1||hepatitis B virus DNA:1||hepatitis B virus surface antigen:1||hepatitis Brelated liver cirrhosis:1||hepatitis C virus:1||hepatitis C virus (HCV):1||hyponatremia:1||iatrogenic gastric ulcer:1||inactive HBsAg carriers:1||inactive carriers:1||index:1||infection:1||infiltrative type:1||inflammation:1||inflammatory bowel disease:1||inspiration:1||insulin resistance:1||intermittent thoracentesis:1||kidney injury:1||lamivudine resistance:1||light:1||liver biopsy:1||liver function:1||liver stiffness measurement:1||liver tumor:1||liverrelated mortality:1||macroglobulin:1||malignant duodenal obstruction:1||mass spectrometry:1||metabolic syndrome:1||metal stent:1||morbidity:1||multicenter study:1||multidrug resistance:1||multiple reaction monitoring:1||necroinflammation:1||necrosis inhibitor:1||neuropsychological:1||neutrophil gelatinaseassociated lipocalin:1||nodular type:1||nonalcoholic fatty liver disease:1||nonreplicative phase:1||normogram:1||nucleotide analogues:1||oncolytic immunotherapy:1||oncolytic vaccinia:1||oral antiviral agent:1||organ failure:1||overall survival:1||overestimation:1||partial virologic response:1||pentoxifylline:1||peroxisome proliferatoractivated receptoralpha:1||pharmacokinetics:1||phase 3:1||pigtail catheter:1||platelet:1||platelettowhite blood cell ratio:1||postoperative complication:1||postoperative mortality:1||precore variant:1||prevalence:1||prognostic efficacy:1||prophylaxis:1||proton pump inhibitors:1||quadruple therapy:1||radiofrequency ablation:1||retreatment:1||realtime PCR:1||ribavirin:1||risk factors:1||risk reduction:1||safety:1||secondline therapy:1||sequential therapy:1||seroclearance:1||serum HBV DNA levels:1||serum HBsAg levels:1||serum biomarker:1||severe alcoholic hepatitis:1||simvastatin:1||single large hepatocellular carcinoma:1||sofosbuvir:1||spleen:1||stage:1||stress:1||subclinical ascites:1||substaging:1||surgery:1||telbivudine:1||terlipressin:1||therapy:1||thoracic duct:1||treatment option:1||validation:1||variceal bleeding:1||varices:1||viral DNA:1||viral suppression:1||virologic response:1||virological response:1||zebrafish:1||간경변:1||간염/바이러스성/만성 B형 간염:1||간염항체:1||감염성 췌장괴사:1||갑상선 자가 항체:1||갑상선기능 이상:1||급성악화:1||급성췌장염:1||내시경 역행성 담췌관조영술:1||내시경역행췌담도조영술:1||내시경적 내부배액술:1||내시경초음파검사:1||다검출 나선 전산화단층촬영:1||담관결석:1||담낭 담석:1||담낭결석:1||담석 성분:1||대장내시경검사:1||독성간염:1||동시성 중복암:1||라미부딘:1||만성 바이러스성 간염:1||만성B형간염:1||복막염:1||분절성 식도 운동장애:1||분절성 저압성 연동운동:1||사망률:1||순간탄성도검사:1||식도 중간부 게실:1||역학:1||예측인자:1||원인 균주:1||유두부암:1||의식하 진정:1||인터페론:1||총담관결석:1||총수담관 결석:1||췌장농양:1||칡즙:1||항균제 내성률:1||AJCC 8th staging system:1||ALAT flare:1||ALBI grade:1||ALT:1||APRI:1||ASCITES:1||Abdomen:1||Abdominal obesity:1||Accreditation:1||Acute exacerbation:1||Acute hepatitis:1||Acute pancreatitis:1||Acuteon:1||Acuteonchronic liver failure:1||Acyclic Nucleotide Phosphonate:1||Adenocarcinoma:1||Adenocarcinoma of the ampulla of Vater:1||Advanced hepatocellular carcinoma:1||Adverse drug event:1||Adverse event:1||Alphafetoprotein:1||Antibacterial agents:1||Antibody titer:1||Antitubercular agent:1||Antiviral:1||Arrowroot:1||Atelectasis:1||Atrial fibrillation:1||Autoimmune:1||Autoimmune pancreatitis:1||B. longum:1||BCLC staging system:1||Bacteria:1||Barcelona Clinic Liver Cancer:1||Barcelona Clinic Liver Cancer stage A:1||Baveno VI criteria:1||Biomarkers:1||Bismuth:1||Body mass index:1||Bone metastasis:1||Bone mineral density:1||Breakthrough:1||B형간염:1||COVID19:1||CTP:1||Cancer screening:1||Carcinoma, hepatocellular:1||Caroli's disease:1||Causality:1||ChildPugh grade:1||Cholangitis:1||Cholelithiasis:1||Chronic Hepatitis B:1||Chronic hepatitis B (CHB):1||Chronic liver disease:1||Chronic viral hepatitis:1||Clevudine:1||Clinical outcome:1||Clinical practice guidelines:1||Clinically significant portal hypertension:1||Cohort:1||Coinfection:1||Colon adenoma:1||Combination:1||Common bile duct stone:1||Compensated advanced chronic liver disease:1||Computed tomography:1||Conscious sedation:1||Coronavirus:1||Coronavirus Disease 2019:1||Crohn's disease:1||Cyanoacrylates:1||Cyclooxygenase 2 inhibitors:1||DNA detection:1||Deformable Registration:1||Deterioration:1||Diagnosis:1||Diagnostic delay:1||Diagnostic screening programs:1||Direct bilirubin:1||Dose Distribution:1||Doubleballoon enteroscopy:1||Drug resistance:1||Duodenal bleeding:1||ERCP:1||Eastern:1||Education:1||Effectiveness:1||Elastography:1||Endoscopic mucosal resection:1||Endoscopic resection:1||Endoscopic retrograde cholangiopancreatography:1||Endoscopic submucosal dissection:1||Endoscopic transmural drainage:1||Endoscopic treatment:1||Enterocolitis:1||Enterolith:1||Enzyme immunoassay:1||Epidemiology:1||Epidermal growth factor receptor:1||Eradication rate:1||Erosive esophagitis:1||Esophageal and gastric varices:1||Esophageal neoplasms:1||Esophagus:1||Ethanol injection:1||Ethiodized oil:1||Fanconi syndrome:1||Fatty liver:1||Fibroscan:1||GSK3389404:1||Gallbladder:1||Gallstone composition:1||Gastric adenoma:1||Gastric cancer:1||Gastric neoplasm:1||Gastric varix:1||Gastrointestinal hemorrhage:1||Genotype 1:1||Glypican3:1||HBV DNA:1||HBV DNA redetection:1||HBeAg:1||

STATISTICS: Total View :12,812,978; Today View :9,635

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE